Correct instructions and guidelines for taking Quizartinib

Quizartinib is an oral kinase inhibitor used to treat FLT3-ITD-positive acute myeloid leukemia (AML). Proper administration and dosage management are critical to drug efficacy and patient safety. The administration of quizartinib is usually divided into three phases: induction therapy, consolidation therapy and maintenance therapy. The dosage and administration regimen of each phase are different.

During the early stages of treatment, known as the induction phase, quizartinib is often combined with other drugs such as cytarabine. During the induction phase, patients were dosed at 35.4 mg once daily for 28 days. The goal of this stage is to quickly control the proliferation of leukemia cells and reduce acute attacks of the disease.

The next step is the consolidation treatment phase, in which the patient continues to take35.4 mg of Quizartinib once a day for 28 days. The goal of consolidation therapy is to eliminate remaining leukemia cells in the body and ensure long-term remission of the disease. At this stage, patients need to undergo regular monitoring based on their doctor's recommendations so that treatment options can be adjusted.

The last is the maintenance treatment phase, which usually begins on the 1st day after induction therapy. The patient's dose is usually adjusted to 26.5 mg once daily. If the patient's QTcF is less than 450ms during treatment, the dose can be gradually increased to 53 mg and continued daily taking. The purpose of maintenance therapy is to control the disease over the long term and prevent leukemia from recurring. Patients need to pay special attention to ECG monitoring during the maintenance phase because the drug may affect the QT interval of the heart.

Quizartinib should be taken regularly, preferably at the same time every day, and patients can choose whether to take it with food according to their personal eating habits. During the treatment process, patients need to regularly check their electrocardiogram and blood routine so that the dose can be adjusted or the treatment plan can be changed in a timely manner.

Keyword tags: Quizartinib,Quizartinib, dosage, induction therapy, consolidation therapy, maintenance therapy, AML, drug dosage, electrocardiogram

References：https://www.ema.europa.eu/en/medicines/human/EPAR/vanflyta